UNC Chapel Hill Gene Therapy Center spinout developing GENV HEM, a universal gene therapy for all types of hemophilia (including patients with inhibitors to clotting factors); pipeline expanded to include a Pompe disease program in 2025.
- HQ
- Chapel Hill
- Sector
- biotech
- Stage
- pre_seed
- Affiliation
- UNC
Founder profiles, enrichment notes, funding history, and investor connections are available to signed-in members.
Sign in to view full record